a16z Bio + Health

Proud to announce Cartography Biosciences’s Series B this morning! Back in 2020, Ansuman Satpathy, Howard Chang, and I started thinking about how to find the next generation of targets in oncology. We were fortunate that Jorge Conde a16z Bio + Health and Sara Choi Wing Venture Capital took a bet on us and the idea, and helped us launch off the ground, and 8VC led our Series A to help us continue to grow. Today, I’m thrilled to welcome Michael Baran from Pfizer Ventures to our board as the lead of our Series B, and Troy Wilson as the chairperson of our board as well. We’re fortunate to be working with them and for the support of all of our other investors and partners. I continue to believe in the need and opportunity of new targets to build new pipelines; that the best therapeutics will come from the best targets. Taking on new biology is a hard challenge, but it’s a challenge worth working on. I couldn’t ask for a better team of people within and around Cartography to be working on it with. https://lnkd.in/gWBiQtgp

First Sessions 2025 Panel Announcement! Get ready for a powerful conversation on Investing in a New Era of Healthcare — kicking off Monday, September 29. Join moderator Jed Brody, Managing Director and Head of Healthcare, Americas at Barclays Capital, alongside an elite panel of leaders: 🔹Adam Boehler, Founder & Managing Partner, Rubicon Founders 🔹 Vijay Jun Patel, Managing Partner, CVS Health Ventures 🔹Julie Yoo, General Partner, a16z In a healthcare landscape shaped by evolving CMS priorities and the “Make America Healthy Again” movement, this panel will dive deep into how political and regulatory shifts are reshaping deal flow, valuations, and risk tolerance. Discover new investment opportunities in key areas like primary care access, behavioral health, home-based care, and cost containment. Learn how capital strategies are evolving for investors and operators alike — and what to watch as we head toward a pivotal 2026. Don’t miss this must-see discussion that sets the tone for the future of healthcare investment. 🔗 Register now for Sessions 2025 and be part of the conversation! https://hubs.li/Q03C8jjC0 Thank you to our Sessions 2025 sponsors Sustaining: Acadia Healthcare, Ascension Saint Thomas, Community Health Systems, HCA Healthcare, Lifepoint Health® & Premise Health Premier: Barclays, Optum, Oracle Health Alliance: athenahealth, Bank of America, Polsinelli & Shearwater Health Vital Edge Sponsors: Alight Solutions, Bass, Berry & Sims, Bradley Arant Boult Cummings LLP, Epstein Becker & Green, P.C., Holland & Knight LLP Podcast Booth: Jefferies News Announcement Sponsor: MEDITECH Get Business Done Lounge Sponsor: Music City PrEP Clinic, Saviynt& TeamHealth Media Partner: Modern Healthcare Host City: Nashville Music City Center Digital Partner: EES Agency Partial sponsor list displayed. Additional 2025 sponsors coming soon.

Final preparations are underway for tomorrow's kickoff of the 11th World Medical Innovation Forum! This exciting event promises to herald new ways forward in medicine and healthcare technology, putting you at the center of where innovation meets patient care. #WMIF2025 #HealthcareInnovation #InnovationatScale

We knew going into #2025USCHA that there was some *magic* in store for Alchemy at this year’s conference! What transpired over a 4-day span was beyond our expectations, and we are so grateful to have worked with Magic Johnson and NMAC to make this event a huge success for the 3000+ attendees in Washington DC. This year’s theme was “Aging with HIV” and we all knew the best way to commemorate this was by bringing on stage the one and only Earvin “Magic” Johnson. Here are some of the many highlights => 💼 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗶𝗰 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 We kicked off an amazing business meeting with Earvin “Magic” Johnson by celebrating the appointment of Harold Phillips as NMAC’s new incoming CEO. We then capped off the morning with a truly unique customer signing event by welcoming AIDS Alabama Inc to the Alchemy portfolio, with Magic helping us mark the occasion. 🤝 𝗠𝗲𝗲𝘁 𝗮𝗻𝗱 𝗚𝗿𝗲𝗲𝘁 𝗘𝘃𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗶𝗰 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 We then transitioned to an intimate Meet and Greet session with select Alchemy and NMAC business partners where everyone had a chance to socialize and take photos with Magic Johnson. There were even some jersey signings and ecstatic fan moments.          🎤 𝗞𝗲𝘆𝗻𝗼𝘁𝗲 𝗖𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 Our Founder & Co-CEO Sid Viswanathan introduced Magic Johnson on stage for a conversation about his life, legacy, and Aging with #HIV. Magic Johnson captivated the audience with a powerful opening keynote sharing his own life experience of being diagnosed and dealing with HIV for over three decades and showing everyone in that room–and beyond what it means to age with HIV gracefully, successfully and with no limitations.  🛠️ 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀 𝘄𝗶𝘁𝗵 𝗢𝘂𝗿 𝗖𝗹𝗶𝗻𝗶𝗰 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 Our team and clinic partners helped amplify the Alchemy mission by sharing practical lessons from our work together, including:  • Addressing the Opioid Use Disorder/HIV/Hepatitis C Syndemic Through Mobile Clinics led by our Founder & Co-CEO Peter Park with our partners from Equality Health Group, Raphael Health Center, and The LGBTQ Center.  • Expanding PrEP Access through Pharmacist-Led Initiation led by our Founder & Chief Pharmacist Susie J. Crowe Crowe with partners from Raphael Health Center, The LGBTQ Center, and NASTAD. At Alchemy we are constantly inspired by the amount of compassion and support that exists within the HIV community, but are also reminded of the amount of work that still remains to improve and advance HIV access and equity across the country. We will continue to focus on building in-house pharmacies inside every HIV clinic in the country to further our mission of ensuring America becomes a place where “Aging with HIV” means every person with HIV has high-quality care and treatment, and ages gracefully–free from stigma and discrimination. #2025USCHA #USCHA #AgingwithHIV NMAC

We are excited to announce today a new collaboration with Eli Lilly and Company to build next-generation #machinelearning models for small molecule design that save time and reduce experimentation cycles. 💻🧪✨ insitro will build advanced ML models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo. Our team will train them on Lilly’s robust, proprietary preclinical data, leveraging a rich set of in vitro and in vivo measurements from a vast array of compounds. The models will address a longstanding challenge in drug discovery: how to predict key pharmacological properties of small molecules.  ⚛️🧪 These properties include Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) which have traditionally been slow and costly to determine through experimental methods in the lab. Small molecules that reach the right tissue at the optimal concentration for the right duration result in better patient outcomes. These models:  ✅ will be trained on data from advanced molecules from decades of Lilly’s drug discovery programs, representing a world-class dataset in quality, consistency and scale ✅ will be available to insitro and our partners, Lilly and their partners, including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge #ML tools to transform medicine discovery ✅ could be a game-changer by giving researchers the ability to zero in on drug-like chemical structures at the earliest stages, avoiding significant wasted work and costly failures Read more in the release here: https://lnkd.in/eeZ-3Pw4

Health 2.0 Redux: PHRs (Personal Health Records) are so back. What else is back? To answer that question, I revisited the startup categories that made the main stage of the 2011 Health 2.0 Conference (the place to be way before HLTH and ViVE) to see which were featured back then, went dormant, and are now rising like a flock of glorious phoenixes from the ashes, mostly in AI-native form. (2011 was the year my personal fave 2010's era PHR app, the *original* 100plus, raised its seed - h/t Chris Hogg). tl;dr - Pretty much all of the 2011 categories map to 2025-era startup activity. Most, if not all, of these categories are looking more viable now than they did 15 years ago for a variety of reasons. So what’s old is new again, but with a confluence of tailwinds that constitute a much stronger “why now.” All this to say - "There are no bad ideas, just bad timing." It’s never been a better time to build in healthcare - this is the industry that will benefit the most from AI, the space is showing signs of evolution that mirror the patterns of earlier eras of the broader tech industry, and traction levels are unprecedented. Full read and 2011-to-2025 category mappings here: https://lnkd.in/ghP_xZmk cc: Matthew Holt, Eva Steinman, Jane Rhee, Andreessen Horowitz

We’re launching the inaugural Prax: AI x Healthcare Summit — happening September 10–11 in NYC! Avon Health and Comma Capital are teaming up to bring together founders, health system execs, policymakers, and investors for unfiltered conversations about what's working in healthcare AI, what's just hype, and what's actually getting adopted. The programming features panels on foundation models, policy roadmaps, and healthtech innovation after AI scribes, with leaders from Kaiser Permanente, Optum, a16z Bio + Health, Bessemer Venture Partners, and more—all in a room full of people building and buying the next wave of healthcare AI. A preview of some of our amazing speakers: Trip Hofer (CEO at Redox, former CEO at Optum), Jay Rughani (Partner at a16z Bio + Health), Ali Khokhar ( Founder & CEO at Amigo), Sofia Guerra (Vice President at Bessemer Venture Partners), and Ashis Barad MD (CTDO at Hospital for Special Surgery). More information about our Title Sponsor and other speakers will be dropped throughout the next few weeks :) Comment “PRAX” to get early access tickets! We have limited tickets available. More information about the summit here: praxsummit.com

I am thrilled to share that we’ve officially launched Skylight Health and closed a $13M financing to help us Make Specialty Care Better for All. After many years as a healthcare executive, this is my first time as a founder—and I couldn't be more excited about the future of Skylight Health. We’re assembling an all-star team to address one of healthcare’s most persistent—and most personal—challenges: fragmented, uncoordinated, and expensive specialty care. Anyone who’s tried to navigate referrals, waitlists, or specialty care silos knows this isn’t just a tech challenge—it’s a human one. It is a hard problem, but it’s also a worthy one and Skylight is here to be part of the solution! We're building a value-based, multispecialty platform designed around the whole person, not just their condition. That includes: ·      A shared data platform to align insights between payors and providers ·      Multispecialty Integration to support specialists and patients, across specialties ·      Local collaboration hubs that bridge the gap between primary and specialty care I am grateful to my co-founder Dr. Doug Smith for his partnership and passion to improve the specialty care experience, and to the team that is already making Skylight a trusted partner for multispecialty care. Special thanks to our investors Valtruis, a16z, and Allen & Company for their conviction in our thesis and team. Our mission is simple but ambitious: to Make Specialty Care Better for All and we are ready to lead the way. Valtruis a16z Bio + Health Allen & Company LLC. Doug Smith Skylight Health